St. Joseph, MO, United States of America

Bernd Colin Eichenmueller



 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Bernd Colin Eichenmueller: Innovator in PCV-2 Compositions

Introduction

Bernd Colin Eichenmueller is a notable inventor based in St. Joseph, MO (US). He has made significant contributions to the field of veterinary medicine, particularly in the development of compositions related to Porcine Circovirus type 2 (PCV-2). His innovative work focuses on enhancing the immunogenicity of these compositions while reducing their virucidal activity.

Latest Patents

Eichenmueller holds a patent titled "Methods of reducing virucidal activity in PCV-2 compositions and PCV-2 compositions with an improved immunogenicity." This invention provides methods for reducing the virucidal activity of a composition that includes a PCV-2 antigen. Additionally, it relates to antigenic preparations and immunogenic compositions that feature a PCV-2 antigen, wherein the virucidal activity has been effectively reduced. The patent also discusses methods for increasing the immunogenicity of these compositions.

Career Highlights

Eichenmueller is associated with Boehringer Ingelheim Vetmedica GmbH, a leading company in the veterinary pharmaceutical industry. His work has contributed to advancements in vaccine development and disease prevention in livestock, particularly in swine health.

Collaborations

Throughout his career, Eichenmueller has collaborated with esteemed colleagues, including Caroline Ann Kohler and Guosong Zhao. These partnerships have fostered innovation and enhanced the research efforts in the field of veterinary medicine.

Conclusion

Bernd Colin Eichenmueller's contributions to the development of PCV-2 compositions highlight his role as an important inventor in veterinary science. His innovative methods aim to improve animal health and welfare through enhanced immunogenicity in vaccine formulations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…